Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InteRNA Technologies has received EUR1.3m Innovation Credit grant from Agentschap, an agency of the Dutch Ministry of Economic Affairs, Agriculture and Innovation, which will support the company for the development of miRNA-based therapeutics for the treatment of melanoma.
Subscribe to our email newsletter
The company said that the purpose of the Innovation Credit is to reduce the financial risk for entrepreneurs and, as such, repayment of the credit, contributing 35% of the total project budget of EUR 3.8m, is subject to the commercial success of the project.
InteRNA CEO Roel Schaapveld said that they are very pleased to receive this funding for the melanoma program as it recognises the innovative character and commercial outlook of this project, a prerequisite to qualify for this facility.
"It allows us to further strengthen the R&D team and speed up the development of our miRNA-based therapy to treat more advanced stages of this aggressive form of cancer for which there currently is no adequate treatment," Schaapveld said.